Table 2.

Clinical-pathological characteristics and subtype distribution of the 4 testing sets^*.

	MDACC		Malaga		Marsden		Edinburgh
	N	%	N	%	N	%	N	%
Treatment	CT		CT		ET		ET
N	272		180		103		120
HER2 status¥
HER2-negative	272	100%	180	100%	89	86%	31	69%
HER2-positive	0	0%	0	0%	14	14%	14	31%
Age (mean)	50.1		50.0		53.7		76.1
Menopausal status
Pre-menopausal	NA		108	60%	0	0%	0	0%
Post-menopausal	NA		72	40%	103	100%	120	100%
Tumor stage
T0-T1	19	7%	18	10%	60	58%	10	9%
T2	142	52%	115	67%			42	36%
T3-T4	111	41%	39	23%	43	42%	63	55%
Node
N0	96	35%	67	37%	61	59%	86	72%
N1	133	49%	61	34%	39	38%	34	28%
N2-N3	43	16%	52	29%	3	3%
Grade
G1	28	11%	27	16%	15	15%	13	11%
G2	136	53%	96	57%	63	62%	82	68%
G3	91	36%	46	27%	24	23%	25	21%
ET response rate§	NA		NA		53%		72%
CT response rate
pCR breast/axilla	8.8%		6.7%		NA		NA
PAM50
Luminal A	141	52%	54	30%	37	36%	-	-
Luminal B	102	38%	105	58%	20	19%	-	-
HER2-E	6	2%	7	4%	12	12%	-	-
Basal-like	7	2%	14	8%	4	4%	-	-
Normal-like	16	6%	-	-	30	29%	-	-

^*ET, endocrine therapy; CT, chemotherapy.

^¥Edinburgh dataset has 75 patients without clinical HER2 status.

^§The definition of ET response is different in the Marsden and Edinburgh datasets. Clinical tumor response (complete and partial response versus stable and progressive disease) was used as the endpoint in the Marsden dataset. Response was evaluated by imaging ultrasound in the Edinburgh dataset. Clinical tumor response was defined as tumor volume shrinkage of at least 70% by 90 days of treatment.